Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation
2022
Abstract
The use of anti-thrombotic therapy is mandatory in classic mechanical circulatory support (MCS) systems in order to decrease the risk of thromboembolic complications associated with poor device hemocompatibility. For most long term MCS, an antiplatelet agent and a vitamin K antagonist (VKA) are both used at therapeutic doses.